Cancer ALK Inhibitor Market, By Drug (Crizotinib (Xalkori), Ceritinib (Zykadia), Alectinib (Alecensa), Brigatinib (Alunbrig), Lorlatinib (Lorbrena)), By Type (First Generation ALK Inhibitors, Second Generation ALK Inhibitors and Third Generation ALK Inhibitors), By Distribution Channel (Hospital Pharmacies, Online Pharmacies and Others), and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Market Trends, Analysis, and Forecast till 2030

Report Code: PMI466521 | Publish Date: August 2023 | No. of Pages: 168

Global Cancer ALK Inhibitor Market Overview

Anaplastic lymphoma kinase is linked with lung cancer and it may be spread to lymph nodes or other organs in the body, such as brain. Metastases is spreading of cancer cell from one organ to another and lung cancer are mainly of two types i.e. small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). NSCLC is any type of epithelial lung cancer other than small-cell lung carcinoma (SCLC) and it accounts for about 85% of all lung cancers. NSCLC are relatively insensitive to chemotherapy compared to small-cell carcinoma. They are primarily treated by surgical resection with curative intent, although chemotherapy is increasing for both preoperatively (neoadjuvant chemotherapy) and postoperatively (adjuvant chemotherapy). These types of NSCLC are squamous-cell carcinoma, large-cell carcinoma and adenocarcinoma. According to Nurse’s Health Study, relative risk of SCC is around 5.5, both among smokers compared with non-smoker.Cancer ALK Inhibitor Market accounted for US$ 1.5 billion in 2020 and is estimated to be US$ 10.6 billion by 2030 and is anticipated to register a CAGR of 22.0%

Impact of Covid-19 pandemic on market

Manufacturing facilities were closed due to worldwide lockdown which delays the growth of the market. Reduced hospital visits and treatment seeking rate due to Covid-19 also hampers the overall market of Androgen receptor inhibitor.

Global Cancer ALK Inhibitor Market Dynamics

Increasing prevalence of Lung cancer

Increasing prevalence of Lung cancer is expected to increase the demand for global androgen receptor inhibitor. Changing lifestyles and other activities like smoking etc. is expected to boost the market for inhibitor demands during forecast period.

Advancement in technology

Cancer patients are looking forward for some advancement in drugs. Further, a large number of companies are now investing into oncology markets to meet the needs of cancer patients. Such companies are contributing for introduction of new drugs with better functionality into market.

Side effects & Unreliable Efficacy

There are many side effects involved in the treatment of this disease. The most common side effect is neutropenia which is temporary and dose-dependent with the white blood count usually return when dose is interrupted or dose is reduce.

Access Crucial Insights at a Fraction of the Cost | Request Your Discount

Global Cancer ALK Inhibitor Market Segmentation

Source: Prophecy Market Insights |Disclaimer: Data is only a representation. Actual data may vary in the final report.

 

Source: Prophecy Market Insights

The Global Cancer ALK Inhibitor Market is segmented based on Drug, type, distribution channel and region.

By Drug, the Global Cancer ALK Inhibitor Market is segmented into Crizotinib (Xalkori), Ceritinib (Zykadia), Alectinib (Alecensa), Brigatinib (Alunbrig), Lorlatinib (Lorbrena). By Type, the market is segmented in First Generation ALK Inhibitors, Second Generation ALK Inhibitors and Third Generation ALK Inhibitors. By Distribution Channel, the Global Cancer ALK Inhibitor Market is segmented into Hospital pharmacies, Online Pharmacies and Others. By region, the Global Cancer ALK Inhibitor Market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. 

Regional Insights:

On region the Global Cancer ALK Inhibitor Market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is expected to dominate the market of Androgen Receptor Inhibitor due to increasing rate of development and commercialization of this inhibitor. Asia-Pacific is expected to be highest growth rate with rising patient population and increasing number of domestic players.

Reduce costs by up to 30% with a custom report tailored to your specific needs | Request Customized Report

Attribute

Details

Base year for estimation

2020

Forecast period

2020 – 2030

Market representation

Revenue in USD Million & CAGR from 2020 – 2030

Market Segmentation

By Drug- Crizotinib (Xalkori), Ceritinib (Zykadia), Alectinib (Alecensa), Brigatinib (Alunbrig), Lorlatinib (Lorbrena).

By Type– First Generation ALK Inhibitors, Second Generation ALK Inhibitors and Third Generation ALK Inhibitors.

By Distribution Channel– Hospital Pharmacies, Online Pharmacies and Others.

Regional scope

North America - U.S., Canada

Europe - UK, Germany, Spain, France, Italy, Russia, Rest of Europe

Asia Pacific - Japan, India, China, South Korea, Australia, Rest of Asia-Pacific

Latin America - Brazil, Mexico, Argentina, Rest of Latin America

Middle East & Africa - South Africa, Saudi Arabia, UAE, Rest of Middle East & Africa

Report coverage

Revenue forecast, company share, competitive landscape, growth factors, and trends

Segments Covered in the Report:

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2019 to 2030. For the purpose of this study, has segmented the Global Cancer ALK Inhibitor Market report based on drug, type, distribution channel and region.

Global Cancer ALK Inhibitor Market, By Region:

      • North America
          • U.S.
          • Canada
      • Europe
          • Germany
          • UK
          • France
          • Russia
          • Italy
          • Rest of Europe
      • Asia Pacific
          • China
          • India
          • Japan
          • South Korea
          • Rest of Asia Pacific
      • Latin America
          • Brazil
          • Mexico
          • Rest of Latin America
      • Middle East & Africa
          • GCC
          • Israel
          • South Africa
          • Rest of Middle East & Africa

Global Cancer ALK Inhibitor Market Key Players

The key players operating in the Global Cancer ALK Inhibitor Market includes AstraZeneca Plc Betta Pharmaceuticals Co. Ltd., Bio-Techne Corp., F. Hoffmann-La Roche Ltd., GlaxoSmithKline Plc, Merck Co., Novartis AG, Pfizer Inc., Takeda Pharmaceutical Co. Ltd., Turning Point Therapeutics Inc. and Xcovery. Companies are continuously rising the production and supply of drug to the

Global Cancer ALK Inhibitor Market Company Profile

  • Turning Point Therapeutics Inc.
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • AstraZeneca Plc
  • Betta Pharmaceuticals Co. Ltd.
  • Bio-Techne Corp.
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline Plc
  • Merck KGaA
  • Novartis AG
  • Pfizer Inc.
  • Takeda Pharmaceutical Co. Ltd
  • Xcovery

 “*” marked represents similar segmentation in other categories in the respective section

Global Cancer ALK Inhibitor Market Table of Contents

  1. Research Objective and Assumption
    • Preface
    • Research Objectives
    • Study Scope
    • Years Considered for the study
    • Assumptions
    • Abbreviations
  2. Research Methodology
    • Research data
    • Primary Data
      • Primary Interviews
      • Primary Breakdown
      • Key data from Primary Sources
      • Key Thickness Insights
    • Secondary Data
      • Major Secondary Sources
      • Secondary Sources
    • Market Estimation
    • Top-Down Approach
      • Approach for estimating Market Share by Top-Down Analysis (Supply Side)
    • Bottom-Up Approach
      • Approach for estimating market share by Bottom-up Analysis (Demand Side)
    • Market Breakdown and Data Triangulation
    • Research Assumptions
  3. Market Purview
    • Executive Summary
    • Key Findings—Global Outlook for Cancer ALK inhibitor Strategies
      • Key Questions this Study will Answer
      • Market Snippet, By Drug
      • Market Snippet, By Type
      • Market Snippet, By Distribution channel
      • Market Snippet, By Region
    • Opportunity Map Analysis
    • Executive Summary—3 Big Predictions
  4. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
      • Market Trends
    • DR Impact Analysis
    • PEST Analysis
    • Porter’s Five Forces Analysis
    • Opportunity Orbit
    • Market Investment Feasibility Index
    • Macroeconomic Factor Analysis
  5. Global Cancer ALK Inhibitor Market, By Drug 2020 – 2030, (US$ Mn)
    • Overview
      • Market Value and Forecast (US$ Mn), and Share Analysis (%), 2020 – 2030
      • Y-o-Y Growth Analysis (%), 2020 – 2030
      • Segment Trends
    •  Crizotinib (Xalkori)
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
    • Ceritinib (Zykadia)
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
    • Alectinib (Alecensa)
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
    • Brigatinib (Alunbrig)
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
    • Lorlatinib (Lorbrena)
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
  6. Global Cancer ALK Inhibitor Market, By Type 2020 – 2030, (US$ Mn)
    • Overview
      • Market Value and Forecast (US$ Mn), and Share Analysis (%), 2020 – 2030
      • Y-o-Y Growth Analysis (%), 2020 – 2030
      • Segment Trends
    • First Generation ALK Inhibitors
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
    • Second Generation ALK Inhibitors
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
    • Third Generation ALK Inhibitors
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
  7. Global Cancer ALK Inhibitor Market, By Distribution Channel, 2020 – 2030, (US$ Mn)
    • Overview
      • Market Value and Forecast (US$ Mn), and Share Analysis (%), 2020 – 2030
      • Y-o-Y Growth Analysis (%), 2020 – 2030
      • Segment Trends
    • Hospital Pharmacies
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
    • Online Pharmacies
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
    • Others
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
  8. Global Cancer ALK Inhibitor Market, By Region, 2020 – 2030, (US$ Mn)
    • Overview
      • Market Value and Forecast (US$ Mn), and Share Analysis (%), 2020 – 2030
      • Y-o-Y Growth Analysis (%), 2020 – 2030
      • Regional Trends
    • North America
      • Market Size and Forecast (US$ Mn), By Drug, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Type, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Distribution Channel, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Country, 2020 – 2030
        • U.S.
        • Canada
    • Europe
      • Market Size and Forecast (US$ Mn), By Drug, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Type, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Distribution Channel, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Country, 2020 – 2030
        • UK
        • France
        • Germany
        • Russia
        • Italy
        • Rest of Europe
    • Asia Pacific
      • Market Size and Forecast (US$ Mn), By Drug, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Type, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Distribution Channel, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Country, 2020 – 2030
        • India
        • Japan
        • South Korea
        • China
        • Rest of Asia Pacific
    • Latin America
      • Market Size and Forecast (US$ Mn), By Drug, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Type, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Distribution Channel, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Country, 2020 – 2030
        • Brazil
        • Mexico
        • Rest of Latin America
    • Middle East & Africa
      • Market Size and Forecast (US$ Mn), By Drug, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Type, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Distribution Channel, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Country, 2020 – 2030
        • GCC
        • Israel
        • South Africa
        • Rest of Middle East
  9. Competitive Landscape
    • Heat Map Analysis
    • Market Presence and Specificity Analysis
  10. Company Profiles
  • Turning Point Therapeutics Inc.
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • AstraZeneca Plc
  • Betta Pharmaceuticals Co. Ltd.
  • Bio-Techne Corp.
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline Plc
  • Merck KGaA
  • Novartis AG
  • Pfizer Inc.
  • Takeda Pharmaceutical Co. Ltd.
  1. The Last Word
    • Future Impact
    • About Us
    • Contact

 

FAQs

The Global Cancer ALK Inhibitor Market is segmented based on drug, type, distribution channel and region.

Increasing prevalence of Lung cancer is expected to increase the demand for global androgen receptor inhibitor. Changing lifestyles and other activities like smoking etc. is expected to boost the market for inhibitor demands during forecast period.

North America is expected to dominate the market of Androgen Receptor Inhibitor due to increasing rate of development and commercialization of this inhibitor. Asia-Pacific is expected to be highest growth rate with rising patient population and increasing number of domestic players.